🇺🇸 FDA
Patent

US 7312340

Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one

granted A61PA61P1/02A61P31/04

Quick answer

US patent 7312340 (Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Dec 20 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Dec 25 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 20 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P1/02, A61P31/04